Sarepta Therapeutics (SRPT) Says Exondys-51 List Price to be $300K/Year
- Wall St. rises amid robust earnings, GDP data
- FBI to review more emails related to Clinton's private email use: letter
- Unusual 11 Mid-Day Movers 10/28: (GRVY) (VRTS) (ITGR) Higher; (OPXA) (SNMX) (STON) Lower
- ExxonMobil (XOM) Tops Q3 EPS by 5c; CapEx Light of Views
- Baker Hughes (BHI), General Electric (GE) in Partnership Talks, Not Merger Talks
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Sarepta Therapeutics (NASDAQ: SRPT) Says Exondys-51 List Price to be $300K/Year
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: Aetna (AET) Adds Sarepta's (NASDAQ: SRPT) Exondys 51 to Coverage List; Will be Effective Nov. 1st
- DragonWave (DRWI) Named as Finalist for Key Industry Award
- Noble Corp (NE) Will Eliminate Quarterly Dividend Payments
Create E-mail Alert Related CategoriesCorporate News, Hot Corp. News, Momentum Movers
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!